4.7 Review

Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients

Journal

BIOMEDICINE & PHARMACOTHERAPY
Volume 163, Issue -, Pages -

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2023.114851

Keywords

Intravenous immunoglobulin; IVIG; COVID-19; SARS-CoV-2

Ask authors/readers for more resources

The COVID-19 pandemic has posed a significant challenge to the health system, and intravenous immunoglobulins (IVIG) have shown potential in reducing inflammation and preventing acute respiratory distress syndrome (ARDS) in severe cases. Previous studies have evaluated the safety and efficacy of IVIG treatment in severe and critical COVID-19 patients, suggesting that early administration of high-dose IVIG may be an effective therapeutic option. However, there is still uncertainty regarding its impact on mortality reduction, and the risk of complications should be considered. Given the limited therapeutic options, the use of IVIG is worth considering.
The coronavirus disease 2019 (COVID-19) pandemic has become a huge obstacle to the health system due to the high rate of contagion. It is postulated that intravenous immunoglobulins (IVIG) can lower the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related inflammation and prevent the development of acute respiratory distress syndrome (ARDS). The main advantages of IVIG treatment might be targeting cytokine storm in severe and critical COVID-19 by influences on complement, innate immune cells, effector T-cells, and Tregs. Randomized clinical trials (RCTs) and non-RCTs evaluating the safety and efficacy of IVIG in patients with se-vere/critical COVID-19 were performed. It seems that early administration of high-dose IVIG (in the acceleration phase of the disease) in severe or especially critical COVID-19 may be an effective therapeutic option, but there are no strong data to use it routinely. The results regarding mortality reduction are inconclusive. Additionally, IVIG treatment carries a risk of complications that should be considered when initiating treatment. However, given the COVID-19 mortality rate and limited therapeutic options, the use of IVIG is worth considering. This review summarizes the development and highlights recent advances in treatment with IVIG of severe/critically ill COVID-19 patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available